Consequently, Piezo2 promoter hypermethylation is not only an LSCC risk factor but also a marker for tumor progression and the presence of metastases, a prediction marker of a patient’s poorer survival, and a possible therapeutic target [76]. The gene discussed is PIEZO2; the disease is neoplasm.